WallStSmart

AbbVie Inc (ABBV)vsU.S. Physical Therapy, Inc. (USPH)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 7855% more annual revenue ($66.01B vs $829.86M). ABBV leads profitability with a 15.7% profit margin vs 3.6%. ABBV appears more attractively valued with a PEG of 0.59. ABBV earns a higher WallStSmart Score of 77/100 (B+).

ABBV

Strong Buy

77

out of 100

Grade: B+

Growth: 6.7Profit: 9.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

USPH

Hold

43

out of 100

Grade: D

Growth: 5.3Profit: 5.0Value: 4.3Quality: 5.5
Piotroski: 3/9Altman Z: 2.22
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-87.6%)

Margin of Safety

-87.6%

Fair Value

$157.25

Current Price

$294.64

$137.39 premium

UndervaluedFair: $157.25Overvalued
USPHUndervalued (+3.2%)

Margin of Safety

+3.2%

Fair Value

$91.07

Current Price

$99.55

$8.48 discount

UndervaluedFair: $91.07Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$520.47B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
36.6%10/10

Strong operational efficiency at 36.6%

EPS GrowthGrowth
2282.0%10/10

Earnings expanding 2282.0% YoY

Debt/EquityHealth
-17.6510/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.598/10

Growing faster than its price suggests

USPH0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

ABBV2 concerns · Avg: 2.0/10
P/E RatioValuation
50.6x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

USPH4 concerns · Avg: 3.0/10
Market CapQuality
$1.49B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.3%3/10

ROE of 0.3% — below average capital efficiency

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 36.6%. Revenue growth of 10.3% demonstrates continued momentum.

Bull Case : USPH

Revenue growth of 13.1% demonstrates continued momentum.

Bear Case : ABBV

The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.6x leaves little room for execution misses.

Bear Case : USPH

The primary concerns for USPH are Market Cap, Return on Equity, Profit Margin. Thin 3.6% margins leave little buffer for downturns.

Key Dynamics to Monitor

ABBV profiles as a mature stock while USPH is a value play — different risk/reward profiles.

USPH carries more volatility with a beta of 1.13 — expect wider price swings.

USPH is growing revenue faster at 13.1% — sustainability is the question.

ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.

Bottom Line

ABBV scores higher overall (77/100 vs 43/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

U.S. Physical Therapy, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

US Physical Therapy, Inc. operates outpatient physical therapy clinics that provide preoperative and postoperative care and treatment for orthopedic-related disorders, sports-related injuries, preventive care, injured worker rehabilitation, and neurology-related injuries. The company is headquartered in Houston, Texas.

Want to dig deeper into these stocks?